NeuroOne Medical Technologies Corporation develops medical technology for surgical diagnosis and treatment of neurological disorders. The company’s platform centers on thin-film electrode technology used in recording, monitoring, mapping, ablation and brain stimulation applications, including Evo Cortical, Evo sEEG and the OneRF Ablation System.
NeuroOne news commonly covers FDA 510(k) clearances, product applications for epilepsy, facial pain and other neurosurgical uses, patent activity around neural probe and electrode technologies, financial results, capital raises, commercial orders, investor conferences and management updates. Coverage also reflects the company’s efforts to extend the OneRF platform into additional ablation, stimulation and drug-delivery applications.
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced a reverse stock split of 1-for-3, effective March 31, 2021, at 4:01 PM ET. This move is part of their strategy to uplist to a major exchange. CEO Dave Rosa highlighted the importance of this step, alongside new institutional investments for product development. Following the split, the number of shares will decrease, impacting stock options and warrants proportionately. NeuroOne continues trading under the symbol NMTC with a new CUSIP number of 64130M 209. The company focuses on advanced solutions for neurological disorders.
NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced that CEO Dave Rosa will appear on the Big Biz Show on April 5, 2021, at 1:15 CST. The discussion will center on the impact of electrical stimulation on treatment modalities and NeuroOne's future role. The company focuses on developing minimally invasive solutions for neurological disorders, including epilepsy and Parkinson's disease. NeuroOne recently completed a milestone with Zimmer Biomet for exclusive distribution rights to its Evo cortical technology, which received FDA clearance in November 2019.
On February 23, 2021, NeuroOne Medical Technologies Corporation (OTCQB: NMTC) announced achieving its first performance milestone under its agreement with Zimmer Biomet, signed on July 20, 2020. The partnership grants exclusive global distribution rights for NeuroOne's Evo™ patented electrode technology and potential back-end milestone payments. CEO Dave Rosa expressed optimism for the company’s future, supported by recent financing of $12.5 million for Nasdaq uplisting and R&D acceleration. NeuroOne aims to enhance brain recording technologies for various neurological disorders.